Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1951 3
1952 4
1953 3
1954 2
1955 2
1957 2
1958 3
1959 4
1960 8
1961 3
1962 2
1963 2
1964 3
1965 8
1966 11
1967 9
1968 12
1969 5
1970 10
1971 5
1972 6
1973 2
1974 4
1975 3
1976 3
1977 10
1978 6
1979 6
1980 9
1981 10
1982 4
1983 4
1984 12
1985 12
1986 15
1987 18
1988 16
1989 16
1990 20
1991 22
1992 18
1993 16
1994 11
1995 11
1996 13
1997 13
1998 4
1999 9
2000 7
2001 8
2002 15
2003 14
2004 13
2005 14
2006 21
2007 27
2008 37
2009 28
2010 23
2011 29
2012 22
2013 22
2014 21
2015 19
2016 21
2017 17
2018 15
2019 19
2020 30
2021 30
2022 35
2023 27

Text availability

Article attribute

Article type

Publication date

Search Results

842 results

Results by year

Filters applied: . Clear all
Page 1
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML, Du J, Pedley A, Assaid C, Strizki J, Grobler JA, Shamsuddin HH, Tipping R, Wan H, Paschke A, Butterton JR, Johnson MG, De Anda C; MOVe-OUT Study Group. Jayk Bernal A, et al. Among authors: brown ml. N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16. N Engl J Med. 2022. PMID: 34914868 Free PMC article. Clinical Trial.
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2.
Brevini T, Maes M, Webb GJ, John BV, Fuchs CD, Buescher G, Wang L, Griffiths C, Brown ML, Scott WE 3rd, Pereyra-Gerber P, Gelson WTH, Brown S, Dillon S, Muraro D, Sharp J, Neary M, Box H, Tatham L, Stewart J, Curley P, Pertinez H, Forrest S, Mlcochova P, Varankar SS, Darvish-Damavandi M, Mulcahy VL, Kuc RE, Williams TL, Heslop JA, Rossetti D, Tysoe OC, Galanakis V, Vila-Gonzalez M, Crozier TWM, Bargehr J, Sinha S, Upponi SS, Fear C, Swift L, Saeb-Parsy K, Davies SE, Wester A, Hagström H, Melum E, Clements D, Humphreys P, Herriott J, Kijak E, Cox H, Bramwell C, Valentijn A, Illingworth CJR; UK-PBC Consortium; Dahman B, Bastaich DR, Ferreira RD, Marjot T, Barnes E, Moon AM, Barritt AS 4th, Gupta RK, Baker S, Davenport AP, Corbett G, Gorgoulis VG, Buczacki SJA, Lee JH, Matheson NJ, Trauner M, Fisher AJ, Gibbs P, Butler AJ, Watson CJE, Mells GF, Dougan G, Owen A, Lohse AW, Vallier L, Sampaziotis F. Brevini T, et al. Among authors: brown ml. Nature. 2023 Mar;615(7950):134-142. doi: 10.1038/s41586-022-05594-0. Epub 2022 Dec 5. Nature. 2023. PMID: 36470304 Free PMC article.
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Titov I, Wunderink RG, Roquilly A, Rodríguez Gonzalez D, David-Wang A, Boucher HW, Kaye KS, Losada MC, Du J, Tipping R, Rizk ML, Patel M, Brown ML, Young K, Kartsonis NA, Butterton JR, Paschke A, Chen LF. Titov I, et al. Among authors: brown ml. Clin Infect Dis. 2021 Dec 6;73(11):e4539-e4548. doi: 10.1093/cid/ciaa803. Clin Infect Dis. 2021. PMID: 32785589 Free PMC article. Clinical Trial.
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.
Motsch J, Murta de Oliveira C, Stus V, Köksal I, Lyulko O, Boucher HW, Kaye KS, File TM, Brown ML, Khan I, Du J, Joeng HK, Tipping RW, Aggrey A, Young K, Kartsonis NA, Butterton JR, Paschke A. Motsch J, et al. Among authors: brown ml. Clin Infect Dis. 2020 Apr 15;70(9):1799-1808. doi: 10.1093/cid/ciz530. Clin Infect Dis. 2020. PMID: 31400759 Free PMC article. Clinical Trial.
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial.
Johnson MG, Puenpatom A, Moncada PA, Burgess L, Duke ER, Ohmagari N, Wolf T, Bassetti M, Bhagani S, Ghosn J, Zhang Y, Wan H, Williams-Diaz A, Brown ML, Paschke A, De Anda C. Johnson MG, et al. Among authors: brown ml. Ann Intern Med. 2022 Aug;175(8):1126-1134. doi: 10.7326/M22-0729. Epub 2022 Jun 7. Ann Intern Med. 2022. PMID: 35667065 Free PMC article. Clinical Trial.
Reply to Sfeir.
Motsch J, Young K, Brown ML, Butterton JR, Paschke A. Motsch J, et al. Among authors: brown ml. Clin Infect Dis. 2021 Apr 26;72(8):1485-1486. doi: 10.1093/cid/ciaa881. Clin Infect Dis. 2021. PMID: 32634242 No abstract available.
Physician Health and Wellness.
McClafferty HH, Hubbard DK, Foradori D, Brown ML, Profit J, Tawfik DS; SECTION ON INTEGRATIVE MEDICINE. McClafferty HH, et al. Among authors: brown ml. Pediatrics. 2022 Nov 1;150(5):e2022059665. doi: 10.1542/peds.2022-059665. Pediatrics. 2022. PMID: 36278292 Review.
Integrative Medicine in Pediatrics.
Weydert JA, Brown ML, McClafferty H. Weydert JA, et al. Among authors: brown ml. Adv Pediatr. 2018 Aug;65(1):19-39. doi: 10.1016/j.yapd.2018.04.011. Epub 2018 Jun 13. Adv Pediatr. 2018. PMID: 30053924 Review. No abstract available.
842 results